- Structural basis of Chikungunya virus inhibition by monoclonal antibodies - pnas.org
- Dengue, chikungunya on the rise in shadow of COVID-19 - Pune Mirror
- Valneva's Chikungunya Vaccine Candidate Awarded EMA Prime Designation - GlobeNewswire
- Chikungunya outbreak in Chad nears 35000 cases since August - Outbreak News Today
- Health emergency declared in West Darfur as chikungunya cases rise - Sudan - ReliefWeb
- Antiviral inhibitor DDX42 shows broad activity against Chikungunya, HIV and SARS-CoV-2 - News-Medical.Net
- Covid-19 Impact on Chikungunya Fever Drugs Market Share, Trends and Growth 2020 to 2025 | Abivax SA, Arno Therapeutics Inc, Bharat Biotech International Ltd, Ennaid Therapeutics LLC, Etubics Corp, Hawaii Biotech Inc - Eurowire
- Chikungunya Vaccine Candidate Awarded EMA Prime Designation - Outbreak News Today
- New Research Report ::Covid-19 impact on Chikungunya Fever Drugs Market Manufacturers Analysis And Industry Insights 2020-2026| Abivax SA, Arno Therapeutics Inc, Bharat Biotech International Ltd, Ennaid Therapeutics LLC, Etubics Corp - Eurowire
- Sudan: Chikungunya outbreak prompts 'State of Emergency' in West Darfur - Outbreak News Today
- Sudan chikungunya outbreak grows in West Darfur - Outbreak News Today
- Do yogasanas daily to get rid of dengue and chikungunya - India TV News
- Chikungunya Fever Drugs Market Drivers, COVID-19 Impact, Trends and Opportunities 2020-2026 | Top Players: Abivax SA, Arno Therapeutics Inc, Bharat Biotech International Ltd - TechnoWeekly
- Chikungunya Fever Drugs Market Research Report 2020 By Segmentations, Key Company Profiles and Demand Forecasts to 2020 to 2026 - Aerospace Journal
- Health ministry rubbishes claims of traditional Chikungunya cures - Khmer Times
